Clinical trial
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or…
NCT00436644 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00436644 |
|---|---|
| Title | Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin |
| Official title | A Phase II Trial of Lapatinib in Combination With Weekly Topotecan in Patients With Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | Lapatinib, Topotecan |
| Enrollment | 18 |
| Start date | Mar 1, 2007 |
| Primary completion | Mar 1, 2009 |
| Completion | Nov 1, 2012 |
| First posted | Feb 19, 2007 |
| Last update posted | Apr 16, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: